Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05777031 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Safety and Efficacy of Collagenase Clostridium Histolyticum After Prior Intralesional PRP for Peyronie's Disease

StatusActive, Not Recruiting
PhasePhase 4
Started2023-10-02
View on ClinicalTrials.gov ↗

Amendment history

2026-06-02
Study Status, Sponsor/Collaborators, Study Design, Contacts/Locations v9
Trial status changed: Recruiting → Active, Not Recruiting
Enrollment reduced: 22 → 12 participants
Study sitesdetails revised at 2 of 2 sites
2026-03-18
Study Status v8
Primary completion date2026-01-15→2027-01-15
Completion date2026-01-15→2027-01-15
2025-01-21
Study Status v7
Primary completion date2025-01-15→2026-01-15
Completion date2025-01-15→2026-01-15
2024-07-01
Study Status v6
Primary completion date2024-07-15→2025-01-15
2023-11-29
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v5
Trial statusNot Yet Recruiting→Recruiting
Start dateestimated 2023-12-01→confirmed 2023-10-02
Study sitesdetails revised at 2 of 2 sites
Show 4 earlier versions
2023-09-14
Study Status v4
Start date2023-09-01→2023-12-01
2023-06-22
Recruiting→Not Yet Recruiting Study Status, Contacts/Locations v3
Trial statusRecruiting→Not Yet Recruiting
Start date2023-06-01→2023-09-01
Study sitesdetails revised at 2 of 2 sites
2023-05-28
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v2
Trial statusNot Yet Recruiting→Recruiting
Study sites1→2
2023-04-07
Study Status v1
Start date2023-05-01→2023-06-01
2023-03-08
Original filing
The purpose of this study is to learn about the safety and side effects of intralesional collagenase clostridium histolyticum (CCH) injected into the Peyronies Disease (PD) plaque after receiving prior treatment with intralesional Platelet Rich Plasma (PRP) injections.
Trial Details
NCT Number NCT05777031
Lead Sponsor University of Miami
Collaborators: Endo USA Inc., a Keenova Therapeutics Company
Conditions Peyronie Disease, Sexual Dysfunctions, Psychological, Genital Diseases, Male
Enrollment 12 participants
Start Date 2023-10-02
Primary Completion 2027-01-15 (estimated)
Study Completion 2027-01-15 (estimated)
Updated on ClinicalTrials.gov 2026-06-04